Interpreting HER2 IHC results is a critical step in the molecular diagnostics of breast cancer, directly influencing treatment eligibility. The assessment requires pathologists to evaluate the intensity and completeness of cell membrane staining in invasive carcinoma cells. This semi-quantitative scoring system provides essential information regarding tyrosine kinase receptor status, helping clinicians determine the appropriateness of targeted therapies.
Understanding the HER2 Protein and IHC Testing
The HER2 protein, encoded by the ERBB2 gene, plays a significant role in cellular growth and differentiation. When amplified or overexpressed, it leads to aggressive tumor behavior but also creates a targetable dependency. Immunohistochemistry (IHC) serves as the primary screening method to quantify protein expression levels within tumor tissue sections.
Specimen Preparation and Technical Assays
Accurate interpretation begins long before the pathologist examines the slide. Standardization of tissue fixation, antigen retrieval, and antibody concentration is paramount to reliable results. Laboratories must utilize validated protocols and appropriate controls to ensure the antibody binds specifically to the HER2 epitope without cross-reactivity.
The Manual Scoring Criteria for HER2 IHC Pathologists assign a score from 0 to 3+ based on the American Society of Clinical Oncology (ASCAP) and College of American Pathologists (CAP) guidelines. The score reflects both the intensity of the membrane staining and the percentage of tumor cells demonstrating complete circumferential membrane staining. Score Definitions and Interpretation Score Staining Intensity Complete Membrane Staining Interpretation 0 Negative Not Amplified 1+ Weak Not Amplified 2+ Moderate Any Reflex ISH Testing 3+ Strong >10% Amplified Challenges in Ambiguous and Tricky Cases
Pathologists assign a score from 0 to 3+ based on the American Society of Clinical Oncology (ASCAP) and College of American Pathologists (CAP) guidelines. The score reflects both the intensity of the membrane staining and the percentage of tumor cells demonstrating complete circumferential membrane staining.
Score Definitions and Interpretation
Not every sample fits neatly into the scoring grid. Cases scoring 2+ often present the greatest diagnostic challenge, requiring reflex fluorescence in situ hybridization (FISH) or chromogenic ISH (CISH) to resolve true genomic status. Artifacts such as crush artifacts, necrosis, or fixation issues can mimic weak positivity, demanding careful technical scrutiny.
Quality Control and Peer Review
To minimize diagnostic errors, robust quality assurance programs are implemented. Many institutions utilize dual-read systems where two pathologists independently score the specimen. Discordance triggers review and discussion, ensuring consensus and adherence to regulatory standards before reporting results to the oncology team.
Clinical Impact and Therapeutic Decision Making
The result of HER2 IHC dictates systemic treatment strategies for the patient. A positive 3+ score typically qualifies the patient for HER2-directed agents like trastuzumab, pertuzumab, and antibody-drug conjugates. Conversely, a 0, 1+, or equivocal result directs the care team toward alternative endocrine or chemotherapy regimens, underscoring the profound impact of this diagnostic test.
